Delivering forward, science-based thinking to help executives and investors mitigate risk and increase success in biopharma innovation.
Identify the companies, programs and investors in your defined market
Develop a nuanced understanding of your target sector with data and analysis
Understand trends and issues shaping the future of your target market
Create a refined target list of potential partners from full biopharma universe
Evaluate potential partners by exploring their pipelines, funding, deals and strategies
Prepare for meetings with both data and context
Identify translational science threats in relevant targets, diseases and technologies
Create alerts for product and strategic developments at competing companies
Monitor investments in your therapeutic and technology spaces
Use Company Profiles to identify comparable programs across the industry
Review investing and partnering deals in your pipeline or program space
Understand where your program fits in the industry pipeline
The authoritative resource to stay up to date with facts, explanation and interpretation.
Complex information, simplified visually.
BioCentury's streaming commentary on industry trends, plus interviews with leading KOLs.
Research and insights on market trends and best practices from BioCentury and our selected sponsors and collaborators.
BioCentury's insights on seminal issues affecting the biotech industry.
Looking ahead to the next generation of biopharma leadership
Stretching the vision of accelerated approval
This week, biotech saw one of its most momentous decisions since the industry’s foundation, with the FDA approval of Biogen’s aducanumab, an anti-amyloid mAb to treat Alzheimer’s
ODAC meeting poses challenges for FDA
The threat of vaccine nationalism and the forces working against it
BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis